Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Peripheral Neuropathy Due to Chemotherapy: early-phase trial registry

7 of 7 indexed Peripheral Neuropathy Due to Chemotherapy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 7 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Peripheral Neuropathy Due to Chemotherapy: 7 US clinical trials tracked, 7 recruiting.

Peripheral Neuropathy Due to Chemotherapy is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition peripheral-neuropathy-due-to-chemotherapy

OPEN 7 | RECR 100% | LATE 0 | EARLY 2 | RANK #2497 | SPON 3

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Peripheral Neuropathy Du (th…100%ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Peripheral Neuropathy Due to Chemotherapy

Peripheral Neuropathy Due to Chemotherapy lists 7 open slots (100% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Peripheral Neuropathy Due to Chemotherapy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Peripheral Neuropathy Due to Chemotherapy is recruiting above its size-band peers.

    7 of 7 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Peripheral Neuropathy Due to Chemotherapy research.

    M.D. Anderson Cancer Center accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Peripheral Neuropathy Due to Chemotherapy trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Peripheral Neuropathy Due to Chemotherapy research is mostly interventional.

    6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Named interventions

Most-linked intervention names on Peripheral Neuropathy Due to Chemotherapy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Qutenza Patch Drug
1 trials
Spinal cord stimulator implant Device
1 trials
oxaliplatin-based chemotherapy Drug
1 trials
Cannabidiol (CBD) Drug
1 trials
Goal Attainment Scaling (GAS) Behavioral
1 trials
Tai Chi Program Behavioral
1 trials
Fall Prevention Training Other
1 trials
Walkasins Device
1 trials

US sites by state

Facility locations filed on Peripheral Neuropathy Due to Chemotherapy trials. A trial with sites in several states counts in each.

Texas 5 trials
Pennsylvania 2 trials
Massachusetts 2 trials
New York 1 trials
Minnesota 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Peripheral Neuropathy Due to Chemotherapy page

7 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 7 Peripheral Neuropathy Due to Chemotherapy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • M.D. Anderson Cancer Center sponsors the most Peripheral Neuropathy Due to Chemotherapy trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peripheral Neuropathy Due to Chemotherapy condition card totals 7 registered trials; most-linked intervention Qutenza Patch; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.